Cabazitaxel, a new-generation taxane that fulfils a hitherto unmet need for second-line chemotherapy in metastatic castrate-resistant prostate cancer, has received approval from the European Medicines Agency. In a recent phase III clinical trial, this drug showed a survival benefit over mitoxantrone; however, it was associated with significant side effects, most notably neutropenia, diarrhoea, nausea/vomiting, peripheral neuropathy and fatigue. Careful patient selection for cabazitaxel is essential, as is a robust management plan for the detection, assessment and prompt treatment of any side effects. This article examines the nurse's role in patient preparation, education, ongoing monitoring and support throughout cabazitaxel treatment.
Written by:
Hardwick J Are you the author?
University Hospitals, Bristol NHS Foundation Trust
Reference: Br J Nurs. 2012 May 10-23;21(9):S13-7
PubMed Abstract
PMID: 22690408